GlassScriptPhysician profile
Avery T Abernathy
NPI 1013207836
$3,379.67
in general payments reported to CMS, 2019-2025
30 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.82 · 2020: $88.68 · 2021: $272 · 2022: $629 · 2023: $657 · 2024: $837 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.37 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $508.34 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $372.57 | 2019-2025 | |
| Lilly USA, LLC | $357.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.40 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $179.34 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $177.09 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $153.93 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $103.53 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $101.67 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $85.21 | 2020-2023 | Belsomra, Steglatro |
| Ibsa Pharma INC. | $64.52 | 2023-2025 | Licart, Tirosint, Flector |
| Novartis Pharmaceuticals Corporation | $49.87 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $44.21 | 2022-2025 | Strensiq |
| Astellas Pharma US INC | $41.84 | 2019-2024 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.54 | 2020-2021 | |
| Exact Sciences Corporation | $41.36 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $31.12 | 2022-2024 | Qelbree |
| Amarin Pharma, INC. | $27.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.26 | 2024-2025 | Eliquis |
| Insulet Corporation | $23.21 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $19.85 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $17.52 | 2025 | Alvesco |
| Boston Scientific Corporation | $17.27 | 2025 | Watchman Flx |
| Sanofi Pasteur INC. | $16.84 | 2022 | |
| Cranial Technologies, INC | $15.74 | 2020 | |
| Sumitomo Pharma America, INC. | $15.46 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $15.17 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $15.05 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Abernathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.